This month’s research round-up covers a number of studies investigating hydroxychloroquine, along with a remdesivir study, the first Phase I vaccine clinical trial and an exploration of the burden of COVID-19 on the healthcare system.
Researchers from Princeton University have uncovered an antibiotic molecule capable of killing both Gram-negative and Gram-positive bacteria using two simultaneous mechanisms, while also avoiding antibiotic resistance.
A drug repurposing survey has identified 30 existing drugs, previously approved for treatment in other diseases, that could be successful in treating COVID-19.
The Anticancer Fund has created an open-access, online database called Covid19db, which shows the COVID-19 clinical trials currently taking place. The database has detected over 200 clinical trials across 35 countries, testing 102 different investigational drugs.
A vaccine against MERS has shown promise in mouse models, potentially aiding the development of a vaccine against COVID-19.
A new study suggests that a human recombinant soluble enzyme blocker, hrsACE2, significantly reduces SARS-CoV-2 viral load in human tissue, suggesting it could have the potential to prevent COVID-19.
Take a look at our day-by-day updates covering the latest on therapeutics and vaccines for COVID-19, from new partnerships to clinical trials..
Take a look behind the scenes of a recent Future Virology editorial entitled, ‘An insight into dengue virus proteins as potential drug/vaccine targets’, as we ask author Muhammad Faheem about recent advances in understanding dengue proteins and where the next 5–10 years could take us.
Catch up on February’s industry headlines, including an MRSA breakthrough, a patent lawsuit, and the latest updates on the coronavirus outbreak and its impact on the biotechnology industry worldwide.
Using machine-learning, researchers have discovered a new antibiotic that is able to kill bacteria resistant to other antibiotics.
